Clinical Proteomics
Scope & Guideline
Empowering Researchers with Open Access to Proteomic Knowledge
Introduction
Aims and Scopes
- Clinical Applications of Proteomics:
The journal focuses on the application of proteomic technologies to discover and validate biomarkers for disease diagnosis, prognosis, and therapeutic monitoring across a variety of conditions, including cancer, cardiovascular diseases, and autoimmune disorders. - Innovative Methodologies:
It emphasizes the development and application of innovative proteomic methodologies, such as mass spectrometry and data-independent acquisition techniques, which enhance the sensitivity and specificity of protein analysis in clinical samples. - Interdisciplinary Research:
The journal encourages interdisciplinary research that combines proteomics with other omics technologies (genomics, transcriptomics, and metabolomics) to provide a comprehensive understanding of disease biology and facilitate personalized medicine. - Biomarker Discovery and Validation:
A significant focus is on the discovery and validation of novel protein biomarkers that can aid in the early detection of diseases, monitor disease progression, and predict treatment responses. - Patient-Centric Studies:
Clinical Proteomics often publishes studies that directly involve patient samples, reflecting real-world clinical scenarios to ensure that findings are applicable and beneficial to patient care.
Trending and Emerging
- Proteomics in Cancer Research:
There is a notable trend in the application of proteomics to cancer research, particularly in understanding tumor heterogeneity, resistance mechanisms, and the identification of novel biomarkers for early detection and targeted therapy. - Integration of Multi-Omics Approaches:
Emerging studies are increasingly integrating proteomics with genomics and metabolomics, allowing for a more comprehensive understanding of biological systems and disease mechanisms, enhancing predictive modeling and personalized medicine. - Machine Learning and Bioinformatics in Proteomics:
The utilization of machine learning and advanced bioinformatics tools to analyze complex proteomic datasets is growing, enabling researchers to uncover patterns that can lead to new insights in disease pathology and treatment responses. - Non-Invasive Biomarker Discovery:
There is a heightened focus on non-invasive proteomic biomarkers derived from bodily fluids (e.g., saliva, urine), which are crucial for developing diagnostic tools that are easier to implement in clinical settings. - COVID-19 Related Proteomics:
The ongoing research related to COVID-19 has led to a surge in publications that explore the proteomic landscape of the virus and its effects on the human body, highlighting the importance of proteomics in understanding infectious diseases.
Declining or Waning
- Basic Research without Clinical Relevance:
Research focusing solely on basic proteomic techniques without direct application to clinical issues has decreased, as there is a growing preference for studies that link proteomics directly to clinical outcomes. - Single Omics Studies:
There has been a decline in publications that focus exclusively on proteomics without integrating other omics approaches, as the trend shifts towards more holistic, multi-omics strategies that provide a more comprehensive view of disease. - Traditional Biomarker Approaches:
The reliance on traditional biomarker discovery approaches, which often do not incorporate advanced proteomic technologies, has waned in favor of more innovative and sophisticated methodologies that offer greater sensitivity and specificity. - Non-Quantitative Proteomics Studies:
The frequency of studies employing qualitative proteomic analyses has decreased, as the field increasingly values quantitative approaches that provide measurable and reproducible results.
Similar Journals
Cancer Genomics & Proteomics
Pioneering discoveries in cancer genomics and proteomics.Cancer Genomics & Proteomics is a pivotal journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of cancer genomics and proteomics. Established in 2004 and running until 2024, this journal provides a vital platform for the dissemination of high-quality research that explores genetic and protein interactions in cancer, thereby fostering innovations in diagnostics and therapeutics. The journal boasts a commendable Q2 ranking in Biochemistry and Genetics and is recognized in the Q3 tier for its contributions to Cancer Research and Molecular Biology, reflecting its growing impact in these dynamic fields. Operating out of Greece, it engages a diverse audience, including researchers, clinicians, and students, by sharing significant findings and methodological advancements in the realm of cancer studies. While currently not an open-access publication, Cancer Genomics & Proteomics remains committed to enriching scientific dialogue and collaboration with its insightful articles and reviews.
Mass Spectrometry Letters
Exploring Innovative Frontiers in Analytical Chemistry.Mass Spectrometry Letters is a pioneering open-access journal published by the Korean Society for Mass Spectrometry, specializing in the diverse fields of analytical chemistry, biochemistry, and spectroscopy. Established in 2010, this journal aims to disseminate groundbreaking research and advancements in mass spectrometry and its applications across various scientific domains. Though currently categorized in the Q4 quartile in key analytical fields, Mass Spectrometry Letters serves as an essential platform for researchers, professionals, and students to share innovative methodologies, emerging trends, and practical applications of mass spectrometry, thus fostering collaboration and advancing knowledge in the scientific community. With a commitment to open access, articles published since 2010 are readily available, enabling widespread distribution and engagement within the international research community. Located in Daejeon, South Korea, and actively converging research through 2024, the journal holds the potential to grow its impact and relevance within the dynamic landscape of mass spectrometry.
JOURNAL OF PROTEOME RESEARCH
Advancing the Frontiers of ProteomicsJOURNAL OF PROTEOME RESEARCH is a premier publication in the field of proteomics, disseminating cutting-edge research and methodologies that drive advancements in biochemistry and molecular biology. Published by the American Chemical Society, this esteemed journal boasts a robust impact, as evidenced by its Q1 rankings in both Biochemistry and miscellaneous Chemistry categories for 2023. With a reputation bolstered by a solid Scopus ranking—#64 out of 408 in General Chemistry and #80 out of 438 in Biochemistry—the journal serves as an essential resource for researchers, professionals, and students aiming to deepen their understanding of protein functions and interactions in biological systems. Although it does not operate under an open-access model, the JOURNAL OF PROTEOME RESEARCH remains a critical platform for scholarly discourse, committed to publishing high-quality, peer-reviewed articles through 2024 and beyond. Scholars are encouraged to engage with the pioneering studies and reviews that shape the future of proteomics.
Genome Medicine
Empowering Progress in the World of Genome MedicineGenome Medicine is a prestigious, peer-reviewed journal published by BMC, focusing on the rapidly evolving fields of genetics, molecular biology, and molecular medicine. Established in 2009 and boasting an open-access format, it has become a leading platform for disseminating high-quality research findings that advance our understanding of genetic diseases and therapeutic innovations. With an impressive Q1 ranking across multiple relevant categories—in particular, genetics (clinical), molecular biology, and molecular medicine—this journal is recognized for its substantial impact in the academic community, as evidenced by its exceptional placement in Scopus rankings. By providing unrestricted access to groundbreaking studies, Genome Medicine fosters collaboration and knowledge sharing among researchers, clinicians, and educators, thus playing a vital role in the transition from fundamental genetic research to clinical applications. Researchers are encouraged to contribute their findings and insights, further solidifying the journal’s position as a pivotal resource for those dedicated to advancing genomic medicine.
Metabolomics
Advancing the Science of MetabolismMetabolomics is a distinguished academic journal published by SPRINGER, dedicated to advancing the field of metabolomics and its applications in various biochemistry-related domains. With a focus on innovative research in biochemistry, clinical biochemistry, and endocrinology, diabetes, and metabolism, this journal holds a significant position, being categorized in the Q2 quartile across multiple fields in the 2023 rankings. The journal is indexed with notable metrics: ranking 73rd in Endocrinology, Diabetes and Metabolism and 38th in Clinical Biochemistry on Scopus, demonstrating its impactful contribution to the scientific community. Established in 2005, Metabolomics provides a vital platform for researchers, professionals, and students to access high-quality research, facilitating advancements in our understanding of metabolic processes and their implications in health and disease. Access options include subscription-based reading, ensuring that valuable insights are available to a broad audience across the globe.
Journal of Proteomics
Shaping the future of biochemistry through proteomics.Journal of Proteomics, published by Elsevier, is an esteemed peer-reviewed journal dedicated to advancing research in the field of proteomics, with broad implications for biochemistry and biophysics. Established in 2008, the journal has continuously evolved, embracing innovative methodologies and technologies that facilitate protein analysis from a variety of biological systems. With its current standing in the Q2 category for both biochemistry and biophysics as of 2023, it is recognized as a significant contributor to scientific literature. The journal publishes original research articles, reviews, and methodological advancements, providing invaluable insights for researchers, professionals, and students alike. Although it does not offer open access, the journal remains a crucial platform for disseminating knowledge that informs various applications, ranging from drug development to disease understanding. As it converges towards 2024, the Journal of Proteomics continues to solidify its role in shaping the future of proteomic research through rigorous scientific inquiry and innovation.
MASS SPECTROMETRY REVIEWS
Fostering Excellence in Mass Spectrometric TechniquesMASS SPECTROMETRY REVIEWS, published by Wiley, is a premier academic journal dedicated to advancing the field of mass spectrometry and its applications across a multitude of scientific disciplines. With an ISSN of 0277-7037 and an E-ISSN of 1098-2787, the journal has established itself as a vital resource within the realms of Analytical Chemistry, Biochemistry, Genetics, Condensed Matter Physics, and Spectroscopy, achieving Q1 status across these categories in 2023. As a testament to its significant contribution to scholarly research, it boasts impressive Scopus rankings, including a rank of #2 out of 76 in Chemistry - Spectroscopy and #4 out of 156 in Chemistry - Analytical Chemistry, placing it in the 97th percentile and above. Emphasizing high-quality, peer-reviewed research, MASS SPECTROMETRY REVIEWS serves as an essential platform for researchers, professionals, and students aiming to stay abreast of cutting-edge developments and methodologies in mass spectrometry. The journal is committed to fostering a deeper understanding of mass spectrometric techniques while also contributing to interdisciplinary advancements, making it a valuable addition to any academic library. Authors seeking to disseminate their work in a journal with a strong reputation and impact in the scientific community will find MASS SPECTROMETRY REVIEWS an ideal venue.
Proteomes, published by MDPI since 2013, is a notable open access journal that occupies a critical place in the realms of Biochemistry, Clinical Biochemistry, Molecular Biology, and Structural Biology. Based in Switzerland, this journal not only promotes the dissemination of high-quality research pertaining to protein structures and functions but also emphasizes interdisciplinary approaches that bridge various fields of biomedical science. With a Category Quartile ranking of Q2 across multiple pertinent categories in 2023, Proteomes boasts a competitive impact within the scientific community, evidenced by its robust Scopus rankings. Researchers, professionals, and students are invited to explore a wealth of pioneering studies and reviews that are made freely accessible, aligning with global trends in open scientific communication. Whether contributing original research or seeking to expand their knowledge, the journal serves as an invaluable resource for anyone engaged in the evolving landscape of proteomics.
Translational Cancer Research
Advancing oncology through groundbreaking research.Translational Cancer Research, published by AME Publishing Company in Hong Kong, is a pivotal journal aimed at fostering the advancement of oncology-related knowledge through the dissemination of high-quality research findings. With its ISSN 2218-676X and E-ISSN 2219-6803, this journal serves as a vital resource for researchers, professionals, and students in the fields of Cancer Research, Oncology, and Radiology, Nuclear Medicine, and Imaging. Established in 2012, the journal covers the latest breakthroughs and cross-disciplinary approaches that drive innovation in cancer treatment and diagnostics. Although currently classified in the Q4 Quartile for Cancer Research and Q3 for both Oncology and Radiology, Translational Cancer Research continuously works toward improving its academic influence and impact, evidenced by its ongoing research contributions. The journal emphasizes open access, making crucial research available to a global audience. We invite scholars and industry professionals to engage with the latest findings and discussions within these critical areas of medical science.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Shaping the Future of Immunological ScienceClinical and Experimental Immunology, published by Oxford University Press, is a premier journal that has been a cornerstone in the field of immunology since its inception in 1966. With an ISSN of 0009-9104 and an E-ISSN of 1365-2249, this journal holds a significant position in academic research, currently ranking in the Q2 category for both Immunology and Allergy (2023). Its impactful contributions are reflected in its Scopus rankings, where it stands at Rank #63 out of 233 in Immunology and Allergy, placing it in the 73rd percentile, and Rank #73 out of 236 in Immunology and Microbiology. Researchers, healthcare professionals, and students will find this journal an invaluable resource for cutting-edge studies, reviews, and clinical advancements in the ever-evolving domain of immunology. While the publication does not offer open-access options, it remains a pivotal platform for disseminating knowledge that impacts both clinical practice and experimental research.